Investors

Creabilis has attracted investment from two of the leading global venture capital firms specialising in life sciences. The Company's €20 million Series A fundraising was led by Sofinnova Partners in collaboration with NeoMed Management.

Sofinnova Partners was founded in Paris in 1972, and is one of Europe's leading independent venture capital firms. With €900 million under management, Sofinnova Partners invests in early stage companies and corporate spin-off in the technology and life sciences sectors - companies that have the potential to become tomorrow's global leaders. Sofinnova Partners has supported entrepreneurs in over 460 ventures throughout Europe and the United States, putting its expertise and international experience to work on their behalf. The companies in its portfolio also benefit from its collaborative relationships with an international syndicate of co-investors, including Sofinnova Ventures, its sister firm in San Francisco.

NeoMed Management is an international investment management firm, based in Oslo, Geneva and the US specializing in the health care and life sciences industry. NeoMed's funds invest in pioneering, development stage companies that have the potential to achieve exceptional growth driven by innovative products. Portfolio companies typically develop improved therapeutics, diagnostics or devices for the treatment of medical needs that are currently unmet or poorly served.